本文選題：重組人生長激素 + 特發(fā)性矮小��； 參考：《中國臨床藥理學(xué)雜志》2017年10期

【摘要】：目的探討重組人生長激素治療特發(fā)性矮小(ISS)患兒的臨床療效及安全性及其與維生素D受體(VDR)啟動子基因多態(tài)性的相關(guān)性。方法選取90例ISS患兒為試驗組,90例同期體檢健康的兒童為對照組。對照組未予以任何處理;試驗組予以重組人生長激素0.15 U·kg~(-1),每晚一次,皮下注射,療程為1年。用測序儀分析2組患兒VDR啟動子中CDX-2結(jié)合位點rs11568820和rs4516035的基因型分布。比較2組患兒不同基因型下的生長速率(GV)、年齡對應(yīng)身高標(biāo)準(zhǔn)差積分(Ht SDSCA)、骨齡對應(yīng)身高標(biāo)準(zhǔn)差積分(Ht SDSBA)、預(yù)測成年身高(PAH),以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果 rs11568820 GG型基因:試驗組治療前和治療后的GV分別為每年(3.12±0.32),(9.61±1.01)cm;Ht SDSCA分別為(0.29±1.32)%,(0.93±0.12)%;Ht SDSBA分別為(0.10±0.15)%,(0.86±0.02)%;PAH分別為(149.02±3.18),(159.02±3.21)cm,差異均有統(tǒng)計學(xué)意義(均P0.05)。rs11568820 GA型基因:試驗組治療前和治療后的GV分別為每年(2.92±1.21),(8.45±1.42)cm;Ht SDSCA分別為(0.42±0.15)%,(0.97±0.13)%;Ht SDSBA分別為(0.16±0.12)%,(0.83±0.13)%;PAH分別為(148.02±3.17),(156.02±3.09)cm,差異均有統(tǒng)計學(xué)意義(均P0.05)。rs11568820 AA型基因:試驗組治療前和治療后的GV分別為每年(3.27±1.21),(8.21±1.43)cm;Ht SDSCA分別為(0.37±0.14)%,(0.82±0.14)%;Ht SDSBA分別為(0.19±0.26)%,(0.79±0.14)%;PAH分別為(149.37±2.91),(158.36±2.83)cm,差異均有統(tǒng)計學(xué)意義(均P0.05)。rs4516035 TT型基因:試驗組治療前和治療后的GV分別為每年(2.71±1.63),(9.32±1.21)cm;Ht SDSCA分別為(0.35±0.21)%,(0.84±0.13)%;Ht SDSBA分別為(0.17±0.23)%,(0.76±0.13)%;PAH分別為(151.13±3.15),(158.23±2.86)cm,差異均有統(tǒng)計學(xué)意義(均P0.05)。rs4516035 CT型基因:試驗組治療前和治療后的GV分別為每年(2.46±1.32),(8.46±1.46)cm;Ht SDSCA分別為(0.32±0.24)%,(0.89±0.13)%;Ht SDSBA分別為(0.17±0.14)%,(0.72±0.13)%;PAH分別為(149.34±3.29),(157.12±3.34)cm,差異均有統(tǒng)計學(xué)意義(均P0.05)。試驗組發(fā)生的藥物不良反應(yīng)主要有血糖升高6例、膝部疼痛4例,其藥物不良反應(yīng)發(fā)生率為11.11%。結(jié)論 ISS與VDR啟動子基因多態(tài)性無顯著相關(guān)性,但與重組人生長激素治療有明顯的聯(lián)系;重組人生長激素治療ISS的臨床療效顯著,且安全性較高。
[Abstract]:Objective to investigate the clinical efficacy and safety of recombinant human growth hormone (rhGH) in the treatment of children with idiopathic dwarf (ISS) and its association with vitamin D receptor (VDR) promoter gene polymorphism. Methods 90 patients with ISS were selected as control group. The control group was not treated with any treatment, and the experimental group was treated with recombinant human growth hormone 0.15 U kg-1, once a night, subcutaneously for one year. The genotypes of CDX-2 binding site rs11568820 and rs4516035 in VDR promoter were analyzed by sequencing. The growth rate (GV), age corresponding height standard deviation score (Ht SDSCA), bone age height standard deviation score (Ht SDSBA), adult height (PAH) and adverse drug reactions were compared between the two groups. Results rs11568820 GG type gene: GV before and after treatment were (3.12 鹵0.32), (9.61 鹵1.01) cm / year in the trial group, (0.29 鹵1.32), (0.93 鹵0.12), (0.10 鹵0.15) in the test group, (149.02 鹵3.18), (鹵159.02 鹵3.21) cm in the trial group, respectively. The difference was significant (all). Rs11568820 GA gene: before and after treatment, the difference was significant (all). Rs11568820 GA gene in the trial group was (149.02 鹵3.18), (鹵159.02 鹵3.21) cm, respectively. 鍒嗗埆涓烘瘡騫，

本文編號：2109826